Epidemiology of SARS-CoV-2 infection in Italy using real-world data: methodology and cohort description of the second phase of web-based EPICOVID19 study - Adorni, Fulvio; Jesuthasan, Nithiya; Perdixi, Elena; Sojic, Aleksandra; Giacomelli, Andrea; Noale, Marianna; Trevisan, Caterina; Franchini, Michela; Pieroni, Stefania; Cori, Liliana; Mastroiannii, Claudio M; Bianchi, Fabrizio; et al. (medRxiv, 2022)
Digital technologies have been extensively employed in response to the SARS-CoV-2 pandemic worldwide. This study describes the methodology of the two-phase internet-based EPICOVID19 survey, and the characteristics of the adult volunteers respondents who lived in Italy during the first (April - May 2020) and the second wave (January - February 2021) of the epidemic. Validated scales and ad-hoc questionnaires were used to collect socio-demographic, medical and behavioural characteristics, as well as information on COVID-19. Among those who provided email addresses during phase I (105,355), 41,473 participated in phase II (mean age 50.7 years ± 13.5 SD, 60.6% females). After a median follow-up of ten months, 52.8% had undergone naso-pharyngeal swab (NPS) testing and 13.2% had positive result. More than 40% had undergone serological test (ST) and 11.9% were positive. Out of the 2,073 participants with at least one positive ST, 72.8% had only negative results from NPS or never performed it. These results indicate that a large fraction of individuals remained undiagnosed, possibly contributing to the spread of the virus in the community. Participatory online surveys offer a unique opportunity to collect relevant data at individual level from large samples during confinement.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04471701 Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Istituto Nazionale per le Malattie Infettive IRCCS Lazzaro Spallanzani approved the EPICOVID19 first (protocol No. 70, 12/4/2020) and second phase (protocol No. 249, 14/1/2021) study protocols. When participants first accessed the web-based platform, they were informed about the study and its purpose, the data to be collected, and the methods of storage; they then filled in the informed consent form. Participants were able to start the EPICOVID19 questionnaire only after consenting. Participation was voluntary and no compensation was given to respondents. The planning, conduct, and reporting of the study were in line with the Declaration of Helsinki, as revised in 2013. Data were handled and stored following the European Union General Data Protection Regulation (EU-GDPR) 2016/679, and housed in the ITB-CNR server in Italy. Data transfer was safeguarded by encrypting and decrypting data and password protection. Study design and data were registered in ClinicalTrials.gov, NCT04471701.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to the authors.